載入...
State of the art in CAR T cell therapy for CD19(+) B cell malignancies
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell malignancies, multiple clinical trials of CAR T cell...
Na minha lista:
| 發表在: | J Clin Invest |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Clinical Investigation
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7108913/ https://ncbi.nlm.nih.gov/pubmed/32235098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129208 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|